Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK poaches Burberry CFO to complete rare all-female executive leadership team
04:58am, Monday, 26'th Sep 2022
GSK PLC (LSE:GSK, NYSE:GSK) poached Burberry Group PLC (LSE:BRBY)'s chief financial officer (CFO) Julie Brown to complete a rare but all-female executive leadership team. Brown will replace Iain Macka
GSK picks Burberry's Brown as first female CFO
02:06am, Monday, 26'th Sep 2022
GSK named luxury fashion brand Burberry's Julie Brown as its first ever female chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its
GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
12:35pm, Saturday, 24'th Sep 2022
British drugmaker GSK plc , has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday.
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
03:02pm, Friday, 23'rd Sep 2022 Zacks Investment Research
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
02:02pm, Friday, 23'rd Sep 2022 Zacks Investment Research
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
Reddit Penny Stocks to Watch as September Ends
10:00am, Friday, 23'rd Sep 2022 PennyStocks
Check these Reddit penny stocks out for your watchlist right now
The post Reddit Penny Stocks to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto
GSK (GSK) Gains As Market Dips: What You Should Know
09:50pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
In the latest trading session, GSK (GSK) closed at $30.01, marking a +0.81% move from the previous day.
7 Stocks to Buy That Can Soar in Good Times or in Bad
04:55pm, Thursday, 22'nd Sep 2022
Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshori
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
03:30pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Reuters
CATL's 3rd Largest Customer After Tesla, Nio Cuts Reliance On Battery Giant In Bid For Diversification
XPeng Inc (NYSE: XPEV) has diversified its battery suppliers and does not count indu
Spero's stock jumps 188% after GSK licenses experimental antibiotic
10:53am, Thursday, 22'nd Sep 2022
Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimen
GSK to shell out an initial US$75mln to gain rights to a next-generation antibiotic
02:57am, Thursday, 22'nd Sep 2022
GSK PLC (LSE:GSK, NYSE:GSK) has inked a licensing deal with a Cambridge, Massachusetts, biotech that will give it access to an oral antibiotic for complicated urinary tract infections. The UK group is
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
04:16pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
01:00pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
10:32am, Wednesday, 21'st Sep 2022
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
